Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 4, 2016. The report serves as a notification of the publication of a Base Prospectus approved by the UK Listing Authority.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the authorization of a debt issuance program rather than reporting operational financial results.
Material Changes
No material changes to financial performance or operations are reported in this document. The primary event is the establishment of a new financing facility.
Guidance, Outlook, and Material Events
- Debt Issuance: The company has published a Base Prospectus for a £15,000,000,000 Euro Medium Term Note Programme involving GlaxoSmithKline plc and GlaxoSmithKline Capital plc.
- Availability: Copies of the Base Prospectus have been submitted to the National Storage Mechanism and are available for inspection via the Morningstar UK website.
- Restrictions: The information is targeted at residents of specific countries as defined in the Base Prospectus and is not intended for use by persons outside these jurisdictions.
Investor Verification Checklist
- Verify the specific terms and conditions of the £15 billion Euro Medium Term Note Programme in the full Base Prospectus.
- Confirm eligibility to access the prospectus based on residency requirements outlined in the document.
- Review the National Storage Mechanism (NSM) for the complete set of incorporated documents.